Latest

Latest oncology News | Page 4

  • Latest oncology news stories and updates. What is happening today? All recent oncology news and developments. Live coverage and timeline of oncology. All you need to know about oncology.
How 12,000 Signatures Helped Change Cancer Care Policy
Survivor Joins Cancer Campaign
Immutep reports positive results from trial of combination cancer therapy
Miles Doing What Matters: Cost-of-living relief to support Queenslanders traveling to access healthcare
Study points at novel approach to treat Group 3 medulloblastoma
Türk deplores wave of strikes killing dozens of civilians, including women and children at hospitals: Ukraine
Immutep reports topline results from TACTI-003 Phase 2b trial
Immutep signs exclusive license agreement with Cardiff University for anti-LAG-3 molecules
Femke Hormann awarded prestigious Junior Research Grant from European Hematology Association
US FDA grants rare paediatric disease designation to Race Oncology’s RC220 bisantrene
Race says bisantrene highly active in a mouse model of multiple myeloma
Icon Group’s Proposed Lease Acquisitions Raise Concerns
Newly established Theranostics Trial Center for cancer diagnostics and therapy
Identifying the initial steps in colorectal cancer formation
European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
CAR T cell therapy targeting HER2 antigen shows promise against advanced sarcoma in phase I trial
BMS and Australian venture capital firm back immunotherapy company Pathios Therapeutics
Cancer Research KI network support translational collaboration in molecular mechanisms at Schulte lab
Funding Boost Supports Future Cancer Experts
Starpharma partners with UK investment firm to create Petalion Therapeutics
Imugene’s oncolytic virotherapy CF33 patent granted in China
Myall Lakes seniors’ concerts raise over $3,000 for palliative care
‘Reaching this point in the development of bisantrene is a major milestone and accomplishment’
Sonia Hancock thanked for pivotal role at Mater Research
Amazing Length Of Service
Sting Operation Out Of Gas
Two datopotamab deruxtecan applications validated in the EU for patients with advanced nonsquamous non-small cell lung cancer or HR-positive, HER2-negative breast cancer
Liberals To Deliver $174.8 Million NWRH And Mersey Master Plan
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer
Tagrisso with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer
Deflexifol clinical data presented at ASCO Gastrointestinal Cancers Symposium
Ramsay Health Care acknowledges World Cancer Day 2024
Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours
Radiotherapy upgrade improves patient care
Imfinzi plus transarterial chemoembolisation (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer…
Voydeya (danicopan) granted first-ever regulatory approval in Japan for adults with PNH to be used in combination with C5 inhibitor therapy
Chiron AS Establishes State-of-the-Art Research Centre in Trondheim, Norway, Advancing Environmental Surveillance
New treatment for deadly uterine cancer
Prescient announces the results of PTX-100 Phase 1b study in T-cell lymphoma patients
Inside Nepean Hospital’s new Pharmacy Department
Examining outcomes in children with Down syndrome and acute lymphoblastic leukemia
Positive efficacy result for Immutep’s ‘efti’ in combination with MSD’s pembrolizumab
Datopotamab deruxtecan improved progression-free survival vs. chemotherapy in patients with previously treated non-small cell lung cancer in TROPION-Lung01 Phase III trial
Datopotamab deruxtecan significantly extended progression-free survival vs. chemotherapy in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
Datopotamab deruxtecan plus Imfinzi demonstrated robust and durable tumour responses in 1st-line treatment of patients with metastatic triple-negative breast cancer in BEGONIA…
Tagrisso plus chemotherapy reduced the risk of disease progression in the brain by 42% in patients with EGFR-mutated advanced lung cancer and…
Imfinzi plus chemotherapy more than doubled pathologic complete response rate in resectable early-stage gastric and gastroesophageal junction cancers versus chemotherapy alone
Free author event at Taree Library

© 2026 - The National Tribune Australia